Merck Serono Aims To Enter Oncology Top Ten In Japan
This article was originally published in PharmAsia News
Executive Summary
Merck Serono’s Japan President Paris Panayiotopoulos said the company aims to rank in the top ten in Japan’s oncology field, mainly by focusing on the flagship drug Erbitux (cetuximab).